8-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  January 8, 2010

ADEONA PHARMACEUTICALS INC.

(Exact name of registrant as specified in its charter)

Nevada	1-12584	13-3808303
(State or other jurisdiction of incorporation)	(Commission File No.)	(IRS Employer Identification No.)

3930 Varsity Drive, Ann Arbor, Michigan 48108

(Address of principal executive offices)  (Zip Code)

Registrant’s telephone number, including area code: (734) 332-7800

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01.                      Regulation FD Disclosure

Steve H. Kanzer, the Chairman of Adeona Pharmaceuticals, Inc. (“Adeona”) will be making a presentation on January 13, 2010 at the One Med Forum in San Francisco, California. In connection with that presentation, he may discuss the slide presentation furnished as Exhibit 99.1 hereto, which is incorporated herein by reference. In advance of his presentation, the Company has posted the accompanying slides on the Investor Relations section of its website, at www.adeonapharma.com.  In addition, Adeona issued a press release that is furnished as Exhibit 99.2 hereto.

The slide presentation attached as Exhibit 99.1 and the press release attached as Exhibit 99.2 to this report include “safe harbor” language pursuant to the Private Securities Litigation Reform Act of 1995, as amended, indicating that certain statements contained in the slide presentation or in the press release are “forward-looking” rather than historical. The slide presentation and the press release also states that these and other risks relating to the Company are set forth in documents filed by the Company with the Securities and Exchange Commission.

The information included in this Item 7.01 and in Exhibit 99.1 and Exhibit 99.2 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 8.01                      Other Events

On January 8, 2010, the Company issued a press release announcing an additional $860,00 grant for oral Estriol Multiple Sclerosis clinical trial and a doubling in the number of clinical sites to speed enrollment in the clinical trial.  The press release is included as Exhibit 99.3 to this Current Report on Form 8-K, incorporated by reference herein, and the description of the press release is qualified in its entirety by reference to such Exhibit.

Item 9.01.                      Financial Statements and Exhibits

(d)           Exhibits

The following exhibits are being filed as part of this Report.

Exhibit Number	Description
99.1	Presentation materials to be provided at the January 13, 2010 Adeona Pharmaceuticals Inc. presentation at the One Med Forum in San Francisco, California.
99.2	Press Release dated January 12, 2010 regarding the presentation to be made on January 13, 2010 by Adeona Pharmaceuticals Inc. at the One Med Forum in San Francisco, California.
99.3	Press release dated January 8, 2010

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ADEONA PHARMACEUTICALS INC.
Date: January 13, 2009	By:  /S/ Steve H. Kanzer
	Name:  Steve H. Kanzer
	Its:  Chairman

EXHIBIT INDEX

Exhibit Number	Description
99.1	Presentation materials to be used at Adeona Pharmaceuticals Inc.’s January 13, 2010 presentation at the One Med Forum in San Francisco, California.
99.2	Press Release dated January 12, 2010 regarding the presentation to be made on January 13, 2010 by Adeona Pharmaceuticals Inc. at the One Med Forum in San Francisco, California.
99.3	Press release dated January 8, 2010

EX-99.1

AMEX: AEN

OneMedForum 2010

January 13, 2010

Forward Looking Statements

AMEX: AEN

the leader addressing

subclinical zinc deficiency

and

chronic copper toxicity

in the

mature population

Copyright © 2008 Pipex Pharmaceuticals, Inc.

AMEX: AEN

Copyright © 2008 Pipex Pharmaceuticals, Inc.

AMEX: AEN

NYSE-Amex Listed: AEN

Founded 2001

$6MM Personally Invested by Chairman

Went Public October 2006

$21MM @$2.00/share 2006-2007

Current Market Cap: $25MM @ $1.19 share

Daily Volume 725,000 shares/day

21MM Primary Outstanding Shares

+3MM Warrants & Options ($1.51 Avg. Exercise Price/Share)

$3,600,000 cash on hand 9/30/09

Average Burn Rate/Qtr. ~$790K

Adeona Corporate Overview

Copyright © 2008 Pipex Pharmaceuticals, Inc.

AMEX: AEN

Launch Date/Status

HartLab: CLIA Certified Reference Lab7/10/09

CopperProof™ Diagnostic Panel11/9/09

Zinthionein™ ZC GS-150 Q1 2010

Zinc-MonocysteineGRAS Process

Oral Estriol for MSPhase II/III

Oral dnaJP1 for RAPhase II Completed

Oral Flupirtine for FMSPhase II IND Approved

Product Pipeline

Copyright © 2008 Pipex Pharmaceuticals, Inc.

AMEX: AEN

David A. Newsome, M.D.
President, HealthMine Subsidiary

Training:

Duke University, A.B.

Columbia University, M.D.

Harvard Medical School, Ophthalmology Residency

(Massachusetts Eye and Ear Infirmary)

Harvard Medical School, Retina Disease and Surgery Fellowship

Bascom Palmer Eye Institute, Retina Disease and Surgery Fellowship

Research & Faculty Experience:

–National Eye Institute (NIH)

•Chief, Retinal Disease Section

–Johns Hopkins, Wilmer Eye Institute, Associate Professor

–LSU Eye Center, Professor

•Author, 150 Peer-Reviewed Publications and 2 books

–Originated Zinc Hypothesis for Age-Related Macular Degeneration

–1988, Published First Clinical Trial, “Oral Zinc Supplementation for Age Related
Macular Degeneration”

–Currently marked as “Preservision”, “Ocuvite” “iCaps”

•2008 Sales ~ $300MM, B&L and Alcon

AMEX: PP

Copyright © 2008 Pipex Pharmaceuticals, Inc.

AMEX: AEN

George J. Brewer, M.D.
Co-Founder, Chair SAB

•Chairman Emeritus, Department of Human Genetics, University of
Michigan

•Foremost Authority on Chronic Copper Toxicity - Wilson’s disease,
>500 Publications

•Member, EPA-Convened National Academy of Sciences -
Committee on Copper in Drinking Water (2000)

•Drawbacks of Galzin®/Wilzin®:

–Nausea in 90% of Patients, G.I. Irritation in 30% of Patients

–3X/day dosing away from meals

•Co-inventor, Adeona Modified-Release Oral Zinc Technology

AMEX: PP, Inc.

AMEX: AEN

Galzin is a registered trademark of Gate Pharmaceuticals Inc.

Copyright © 2008 Pipex Pharmaceuticals, Inc.

AMEX: AEN

Diseases of Confirmed or Suspected
Copper/Zinc Dyshomeostasis

DISEASE	U.S. PERSONS
Wilson’s Disease	10,000
Dry Age-Related Macular Degeneration	17,000,000
Alzheimer’s Disease	5,800,000
Mild Cognitive Impairment	15,000,000
Parkinson’s Disease	400,000
Complications of Diabetes	23,000,000
Estimated Total U.S. Persons	50,000,000

Copper’s
Involvement
in
Alzheimer’s
and Mild
Cognitive
Impairment

(COPPER)

(Copper)

(Copper)

(Copper)

(Copper)

(Copper)

Courtesy: NIA;

“Copper” Text Added.

5.3 Million Miles of Copper Tube in U.S.

Current EPA Limit of Copper in Water:
1.3mg/L

Average Home has About 1/10th the EPA Limit

Copper-Containing Multivitamins and
Cognitive Decline in the CHAP Study (2006)

•Chicago Health and Aging Project (CHAP)

•3718 Chicago Residents over Age 65

•Cognition Tested at 0, 3 and 6 Years

•Copper-Containing Multivitamin Consumption
Noted and Compared

•Consumers of Copper-Containing
Multivitamins (i.e. 2mg/day) with a High Fat
Diet had 6.51 Times the Rate of Cognitive
Decline than Persons not taking Copper-
Containing Multivitamins

AMEX: AEN

Morris MC et. al., Arch. Neurol. Vol. 63;1085-8 (Aug 2006)

Chicago Health and Aging Project (CHAP)

AMEX: AEN

Serum Copper Dyshomeostasis in AD & MCI

Free Copper Ions	0	0.0001
Homocysteine	<10	<0.5%
Ferroxidase II	<10	<0.5%
Extracellular SOD	<10	<0.5%
Factors V and VIII	<5	<0.5%
Metallothionein	<1	<0.1%
15-60kDa Proteins	40	<0.5%
Small Peptides	35	<0.5%
Albumin	150	15%
Ceruloplasmin	700	70%

%

µg/L

Copper

Bound

To

Cerulo-

Plasmin

(Cp)

Free

Copper

Copper

Bound

To

Cerulo-

Plasmin

(Cp)

Free

Copper

Normal

Wilson’s

AMEX: PP

Copyright © 2007 Pipex Pharmaceuticals, Inc.

Free

Copper

Copper

Bound

To

Cerulo-

Plasmin

(Cp)

Alzheimer’s
& MCI

Linder et. al.

Serum Copper/Zinc Dyshomeostasis in
Alzheimer’s Disease

•Elevated Percent Serum Free Copper in AD

–Distinguishes AD from Normals (Squitti et. al. 2005)

–Prognostic for Cognitive Decline (Squitti et. al Jan. 2009)

–Correlates with Cognitive Loss (Arnal N, et. al. Dec. 2009)

•Defective Ceruloplasmin (Squitti et. al. Jan. 2008)

CopperProof-1 Study

•90 Subject Prospective, Observational, IRB-Approved
Randomized Comparative Study

•Sponsored by Adeona

•The Alzheimer’s Center at Albany Medical Center - P.I. Earl
Zimmerman, M.D.

•30 Alzheimer’s, 30 Parkinson’s, 30 Age-Matched Normals

•Patients Recruited 2007-2008. Analysis Q1 2009

•Results Presented at ICAD (International Conference on
Alzheimer’s Disease) July 15, 2009

•Acquisition by Adeona - July 10, 2009

•CLIA-Certified Laboratory, Chicago

•Launched CopperProof™ Panel - Nov. 2009

•Serum-Based Copper/Zinc Diagnostic Panel

•Diagnose and Grade Patients with
Copper/Zinc Dyshomeostasis (AMD, AD, MCI,
PD etc.)

•Dx-Rx Strategy - Zinthionein™ ZC GS-150

Zinthionein™ ZC GS-150 Oral Zinc

Gastroretentitive/Sustained Release Oral High Dose Zinc
Preparation

Convenient Once-a-Day Dosing (vs. 3X Galzin® or 2X
AREDS)

Broad Patent Protection Anticipated

100% GRAS Ingredients

Highest Single Dose Bioavailability of Oral Zinc in Humans

Extended Sustained Serum Zinc Levels Maintained

Proximal Metallothionein Induction

Intended Lower Instance of Nausea and Gastric Irritation
(vs. 90% for Galzin® at 1/3 Dose)

Planned Launch this Quarter

•Medical Foods:

–Legislation Section 5 of Orphan Drug Act

–GRAS Ingredients “Intended fro the Dietary
Management of Disease or Condition not
Satisfied by Normal Diet Alone”

–Exempt from NDA Requirements

–Must be Sold Under Doctors’ Supervision

•Prescription Product

•Distributed through Pharmacy Distribution
Chain

–Reimbursement Generally Available

Copyright © 2008 Pipex Pharmaceuticals, Inc.

AMEX: AEN

CopperProof-2 Clinical Trial

•First Controlled Clinical Trial of Zinc therapy for AD or MCI

•60 Patient, Two Part, Double Blind, Randomized Placebo Controlled
Trial of Once-Daily Zinthionein™ ZC GS-150 in AD and MCI Patients with
Impaired Serum Copper/Zinc Status

•P.I. Diana Pollack, Alzheimer’s Center - Clearwater Hospital, Florida

•IRB Approved November 2nd, 2009

•30 Day Washout Period for Copper Supplements

•Part I:Single Day Comparison to Galzin® and Placebo

–Endpoint: Improved bioavailability and tolerability

•Part II:6 Month, Double Blind Randomized Placebo Controlled Study

–Endpoint: Cognition, MMSE and ADAS-Cog at 3 and 6 months

•Initial Data Expected Next Month (February)

* Zinthionein™ ZC contains 150mg elemental zinc
and does not contain zinc-monocysteine.

- Issued Composition of Matter Patents

•U.S. Patent 7,164,035, Issued Jan. 16, 2007

•U.S. Patent 6,586,611, Issued July 1, 2003

–Additional pending patents pending

–Modified Release Zinc - GR, SR, High Dose, Once-Daily

–Combination formulas

–Copper-free formulas

–Pill dispenser that incorporates eye self-test

–Serum based diagnostic assays

–Trademarks:

•Zinthionein®, Eyedaily®, (888) EYE-DAILY,
www.eyedaily.com

Copyright © 2008 Pipex Pharmaceuticals, Inc.

AMEX: AEN

AMEX: AEN

ADDITIONAL CLINICAL PROGRAMS
FOR WHICH ADEONA IS SEEKING
BUSINESS DEVELOPMENT
OPPORTUNITIES

TRIMESTATM (oral estriol) for Multiple Sclerosis

•Approved in Europe & Asia for 40 years (No U.S.)

•Oral Version of Endogenous Pregnancy Hormone

–Estriol or E3

•First Potential Oral Treatment for MS

•Developed by Rhonda Voskuhl M.D.

–Chair UCLA MS Neurology Center

•Exclusively Licensed from UCLA

•Believed to be Responsible for:

–Fetal Immune Privilege

–Spontaneous Remission of Autoimmune Diseases

•Completed 22 Month Phase IIa Clinical Trial under
funding from the NMSS

AMEX: PP

Copyright © 2008 Pipex Pharmaceuticals, Inc.

AMEX: AEN

79% Reduction in MRI Lesions @ 3 Months (p=0.02)
Lower number of lesions and lower lesion volume while on Trimesta

New Enhancing Lesion Numbers

New Enhancing Lesion Volumes (mm3)

TRIMESTA(19-22)

Post Tx (16-18)

Post Tx (13-15)

Pre Tx (1-6)

*

*

*

*

*

Months Tx

Copyright © 2008 Pipex Pharmaceuticals, Inc.

AMEX: AEN

Improvement In Cognitive Function By
14% in 6 months (p=0.04)

6 RR TrimestaTx (month 12)

6 RR Pre Tx (month 3)

4 SP TrimestaTx (month 12)

4 SP Pre Tx (month 3)

All 10 TrimestaTx (month 12)

All 10 Pre Tx (month 3)

*

AMEX: AEN

TRIMESTA™ Phase II/III Clinical Trial

•Phase II/III Clinical Trial In MS

–150 Patients, 71 Enrolled

–16 U.S. Centers

–Double-Blind, 1:1 Placebo Design with Copaxone as Standard of Care

–Female Relapsing-Remitting Patients

–Funded by $5 Million NIH/National MS Society Grant

•Largest Clinical Grant Ever Awarded by NMSS

•Recent Additional $860,000 Grant under ARRA

–Primary Endpoint

•Relapse Rate at 2 Years with Interim Analysis at 1 Year

–Secondary Endpoints

•Cognitive Tests-PASAT

•NAA levels

•MRI

•Hippocampus volume

AMEX: AEN

AMEX: AEN

Oral mucosal route induces immune tolerance

to the epitope-specific antigens

AMEX: AEN

•Double-Blind, Placebo-Controlled Phase II Clinical Trial

•Active RA patients

•Background Therapy Medications Allowed

•11 Clinical Centers

•Stanford, UCSD, U. Arizona, John Hopkins, Mayo Clinic

•Daily oral administration, 6 months

•160 patients: 1:1 randomization

•Enrollment criteria based on presence of both immunological reactivity to HSP-
dnaJP1 and clinically active disease

•Endpoints:

•Clinical Endpoints:ACR 20, ACR50

•ACR20: FDA approvable endpoint

•Immunologic Endpoints

AMEX: AEN

Published Results of Phase II Study

•dnaJP1 appeared to be safe and well-tolerated.

•There was a significant reduction in the percentage of T cells producing the
proinflammatory cytokine tumor necrosis factor alpha (TNF-alpha) (p < 0.0007).

•The primary efficacy end point (meeting the American College of Rheumatology
20% improvement criteria at least once on day 112, 140, or 168) showed a
difference between treatment groups (p=0.09) that became significant in post hoc
analysis using generalized estimating equations (p=0.04).

•Differences in clinical responses were also found between treatment groups on
day 140 and at follow up, indicative a durable response following discontinuation
of therapy.

Arthritis & Rheumatism, Nov. 2009

•Oral flupirtine

–Developed by Andrew Stoll M.D.

•Experimental Pharmacology, McLean Hospital/Harvard University

–Oral flupirtine, marketed in Europe since 1984

•Potassium Channel Modulator

•In-direct NMDA receptor antagonist

•Non-opioid, centrally acting analgesic compound

•New mechanism of action

–Issued U.S. Patent, pending international patents

–Pilot human results in refractory fibromyalgia patients

•~24 patients in fibromyalgia

•~150 patient clinical results in glaucoma, retinitis pigmentosa, diabetic retinopathy

–Phase II ready clinical trial in refractory fibromyalgia

•IND Approved

•IRB Approval Received

AMEX: AEN

Steve H. Kanzer, CPA, JD

Chairman

Adeona Pharmaceuticals, Inc.

3930 Varsity Drive

Ann Arbor, Michigan 48108

Phone: (734) 332-7800

Fax: (734) 332-7878

www.adeonapharma.com

Copyright © 2010 Adeona Pharmaceuticals, Inc.

AMEX: AEN

EX-99.2

EXHIBIT 99.2

Adeona to Present at OneMedForum 2010 San Francisco

Ann Arbor, MI,  January 12, 2010, Adeona Pharmaceuticals, Inc., (AMEX:AEN - News), a specialty pharmaceutical company dedicated to the awareness, diagnosis, prevention and treatment of zinc deficiency and chronic copper toxicity in the mature population, announced today that that Steve H. Kanzer, CPA, JD, Chairman of Adeona, will present at the OneMedPlace Finance Forum 2010 at 12:15 p.m. (PT) on Wednesday, January 13, 2010 at The Sir Francis Drake Hotel, 450 Powell Street at Sutter, Union Square, San Francisco, CA.

About the OneMedForum 2010

Held annually in San Francisco, the OneMedPlace Finance Forum was created to connect emerging healthcare and life science companies with investors and strategic partners. Over 100 company presentations will occur by some of the most promising - and typically least recognized - companies in the world. Recognizing the impacts and opportunities connected to healthcare reform and the stimulus package, the conference has added a third day dedicated to Health Information.

More information is available at http://www.onemedplace.com/onemedforum/index.php.

About Adeona Pharmaceuticals, Inc.

Adeona Pharmaceuticals, Inc. (AMEX: AEN) is a specialty pharmaceutical company dedicated to the awareness, diagnosis, prevention and treatment of zinc deficiency and chronic copper toxicity in the mature population. Adeona believes that these conditions may contribute to the progression of debilitating degenerative diseases, including, Dry Age-Related Macular Degeneration (Dry AMD), Alzheimer's disease (AD) and mild cognitive impairment (MCI) in susceptible persons. Using Adeona’s proprietary, modified oral zinc delivery technologies, Adeona is preparing to initiate the first clinical trial of oral zinc therapy for the once-a-day dietary management of AD and MCI. Adeona is also developing a number of late-stage clinical drug candidates for the treatment of rheumatoid arthritis and multiple sclerosis. For further information, please visit www.adeonapharma.com.

This release includes forward-looking statements on Adeona's current expectations and projections about future events. In some cases forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions. These statements are based upon current beliefs, expectations and assumptions and are subject to a number of risks and uncertainties, many of which are difficult to predict and include statements regarding designing additional clinical trials for its oral zinc therapies, dnaJP1, Zinthionein, Zinthionein ZC, flupirtine, or Trimesta. Adeona is at an early stage of development and may not ever have any products that generate significant revenue. Adeona’s Hartlab subsidiary is generating modest revenues and its future success will likely depend upon its ability to successfully introduce and market new specialty diagnostic assays to generate additional revenues. Important factors that could cause actual results to differ materially from those reflected in Adeona's forward-looking statements include, among others, a failure of Adeona's product candidates to be demonstrably safe and effective, a failure to obtain regulatory approval for the company's products or to comply with ongoing regulatory requirements, regulatory limitations relating to the company's ability to promote or commercialize its products for awareness, prevention, diagnosis or treatment of zinc deficiency and chronic copper toxicity, a lack of acceptance of Adeona's product candidates in the marketplace, a failure of the company to become or remain profitable, that we will continue to meet the continued listing requirements of the American Stock Exchange (which, unlike other exchanges, does not require us to maintain any minimum bid price with respect our stock but does require us to maintain a minimum of $6 million in stockholders' equity during the current year, for example), our inability to obtain the capital necessary to fund the company's research and development activities, a loss of any of the company's key scientists or management personnel, and other factors described in Adeona's report on Form 10-K for the year ended December 31, 2008, Forms 10-Q for quarters ending in 2009 and any other filings with the SEC. No forward-looking statements can be guaranteed and actual results may differ materially from such statements. The information in this release is provided only as of the date of this release, and Adeona undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.

For Further Information Contact:

Steve H. Kanzer, CPA, JD

Chairman

(734) 332-7800 x39

EX-99.3

EXHIBIT 99.3

Adeona Announces Additional $860,000 Grant

for Oral Estriol Multiple Sclerosis Clinical Trial

Number of Clinical Sites Doubled To Speed Enrollment

Ann Arbor, MI,  January 8, 2010, Adeona Pharmaceuticals, Inc., (AMEX:AEN - News), a specialty pharmaceutical company dedicated to the awareness, diagnosis, prevention and treatment of zinc deficiency and chronic copper toxicity in the mature population, announced today that the ongoing clinical trial of its Trimesta™ (oral estriol) drug candidate being conducted by Dr. Rhonda Voskuhl, Director, UCLA Multiple Sclerosis Program, UCLA Dept. of Neurology has received an additional $860,440 in grant funding through the American Recovery and Reinvestment Act. The current phase II/III clinical study is a double-blind, placebo-controlled trial taking place at sixteen sites in the US and will enroll up to 150 female Multiple Sclerosis (MS) patients. Investigators will administer Trimesta along with glatimer acetate (Copaxone®), an FDA approved therapy for MS, to women between the ages of 18-50 who have been recently diagnosed with relapsing-remitting MS. This ongoing clinical trial previously received a $5 million grant from the National Multiple Sclerosis Society (NMSS) in partnership with the National MS Society’s Southern California chapter, with support from the National Institutes of Health (NIH).

According to Dr. Voskuhl, "This additional funding has already had a very positive impact on our trial. It has greatly increased the rate of enrollment by supporting the addition of 9 more clinical sites, bringing the total up to 16 sites across the US. We were extremely pleased that our trial was deemed important enough to be supplemented with these additional funds."

Previous Phase II Clinical Trial Results in Relapsing Remitting Multiple Sclerosis

Trimesta (oral estriol) has previously completed an initial 22-month, single-agent, crossover Phase I/II clinical trial in the US for the treatment of MS in relapsing remitting patients, with highly encouraging results. The results showed the total volume and number of enhancing pathogenic myelin lesions (established neuroimaging measurements of disease activity in MS) decreased during the treatment period as compared to a six-month pretreatment baseline period. The median total enhancing lesion volumes decreased by 79 percent (p=0.02) and the number of lesions decreased by 82 percent (p=0.09) within the first three months of treatment with Trimesta.  Following a six-month drug holiday during which the patients weren’t on any drug therapies, Trimesta therapy was reinitiated during a four-month retreatment phase of this clinical trial. The relapsing-remitting MS patients again demonstrated a decrease in enhancing lesion volumes of 88 percent (p=0.008) and a decrease in the number of lesions by 48 percent (p=0.04) compared with original baseline scores (1),(2).

Improvement in Cognitive Testing Scores

During the prior Phase I/II clinical trial, a 14-percent improvement in Paced Auditory Serial Addition Test (“PASAT”) cognitive testing scores (p=0.04) was also observed in the MS patients at six months of therapy. PASAT is a routine cognitive test performed in patients with a wide variety of neuropsychological disorders such as MS. The PASAT scores were expressed as a mean percent change from baseline and were significantly improved in the relapsing-remitting group.

About the Trimesta Phase II/III Study

In the current phase II/III study, Trimesta is being given orally once-a-day versus placebo to 150 female relapsing-remitting MS patients in combination with a standard of care background therapy, subcutaneously injected glatimer acetate. The primary endpoint for the study will evaluate effects of the treatment combination on relapse rates at two years with a one year interim analysis using standard clinical measures of MS disability as well as secondary endpoints of magnetic resonance imaging measurements of brain lesion and effects on cognition.  The study is approaching 50% enrollment with the rate of enrollment benefiting significantly from the expansion of clinical sites.

About Trimesta

Trimesta is an orally active, immunomodulatory and anti-inflammatory molecule which has been approved and marketed throughout Europe and Asia for approximately 40 years for the treatment of post-menopausal hot flashes, but which has never been introduced in North America. Estriol, the active ingredient in Trimesta, is a weak estrogenic-based molecule that is produced in the placenta by women during pregnancy. Estriol is considered to play an important role in the immunologic privilege offered to the fetus during pregnancy, and is also thought to be responsible for the spontaneous remission of Th1-mediated autoimmune diseases of women (such as multiple sclerosis and rheumatoid arthritis) during pregnancy, especially during the third trimester. Adeona has an exclusive worldwide license from UCLA to issued and pending patents invented by Dr. Voskuhl including U.S. Patent 6,936,599 covering estriol’s use for MS.  While currently marketed therapies for MS sell billions of dollars annually, all require frequent injections and currently is no FDA-approved oral therapy for the treatment of MS.

About Adeona Pharmaceuticals, Inc.

Adeona Pharmaceuticals, Inc. (AMEX: AEN) is a specialty pharmaceutical company dedicated to the awareness, diagnosis, prevention and treatment of zinc deficiency and chronic copper toxicity in the mature population. Adeona believes that these conditions may contribute to the progression of debilitating degenerative diseases, including, Dry Age-Related Macular Degeneration (Dry AMD), Alzheimer's disease (AD) and mild cognitive impairment (MCI) in susceptible persons. Using Adeona’s proprietary, modified oral zinc delivery technologies, Adeona is preparing to initiate the first clinical trial of oral zinc therapy for the once-a-day dietary management of AD and MCI. Adeona is also developing a number of late-stage clinical drug candidates for the treatment of rheumatoid arthritis and multiple sclerosis. For further information, please visit www.adeonapharma.com.

This release includes forward-looking statements on Adeona's current expectations and projections about future events. In some cases forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions. These statements are based upon current beliefs, expectations and assumptions and are subject to a number of risks and uncertainties, many of which are difficult to predict and include statements regarding designing additional clinical trials for its oral zinc therapies, dnaJP1, Zinthionein, Zinthionein ZC, flupirtine, or Trimesta. Adeona is at an early stage of development and may not ever have any products that generate significant revenue. Adeona’s Hartlab subsidiary is generating modest revenues and its future success will likely depend upon its ability to successfully introduce and market new specialty diagnostic assays to generate additional revenues. Important factors that could cause actual results to differ materially from those reflected in Adeona's forward-looking statements include, among others, a failure of Adeona's product candidates to be demonstrably safe and effective, a failure to obtain regulatory approval for the company's products or to comply with ongoing regulatory requirements, regulatory limitations relating to the company's ability to promote or commercialize its products for awareness, prevention, diagnosis or treatment of zinc deficiency and chronic copper toxicity, a lack of acceptance of Adeona's product candidates in the marketplace, a failure of the company to become or remain profitable, that we will continue to meet the continued listing requirements of the American Stock Exchange (which, unlike other exchanges, does not require us to maintain any minimum bid price with respect our stock but does require us to maintain a minimum of $6 million in stockholders' equity during the current year, for example), our inability to obtain the capital necessary to fund the company's research and development activities, a loss of any of the company's key scientists or management personnel, and other factors described in Adeona's report on Form 10-K for the year ended December 31, 2008, Forms 10-Q for quarters ending in 2009 and any other filings with the SEC. No forward-looking statements can be guaranteed and actual results may differ materially from such statements. The information in this release is provided only as of the date of this release, and Adeona undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.  Copaxone® is a registered trademark of Teva Neurosciences, Inc.

For Further Information Contact:

Steve H. Kanzer

Chairman

(734) 332-7800 x39